Already a Bloomberg.com user?
Sign in with the same account.
Don't have an account?
Help! I can't access my account.
Genentech's Herceptin is the first drug to target a cancer-causing genetic defect. It blocks a gene found in 30% of breast-cancer victims. (800) 626-3553
Max 250 characters
©2013 Bloomberg L.P. All Rights Reserved. Made in NYC